Literature DB >> 17476350

Principles of adoptive T cell cancer therapy.

Carl H June1.   

Abstract

The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy. For example, use of engineered T cells is being tested as a strategy to improve the functions of effector and memory T cells, and manipulation of the host to overcome immunotoxic effects in the tumor microenvironment has led to promising results in early-stage clinical trials. Challenges that face the field and must be addressed before adoptive T cell therapy can be translated into routine clinical practice are discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17476350      PMCID: PMC1857246          DOI: 10.1172/JCI31446

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  123 in total

1.  Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27.

Authors:  Ruth D Fritsch; Xinglei Shen; Gary P Sims; Karen S Hathcock; Richard J Hodes; Peter E Lipsky
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

2.  Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

Authors:  Juhua Zhou; Xinglei Shen; Jianping Huang; Richard J Hodes; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

3.  Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.

Authors:  Naoto Hirano; Marcus O Butler; Zhinan Xia; Sascha Ansén; Michael S von Bergwelt-Baildon; Donna Neuberg; Gordon J Freeman; Lee M Nadler
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

4.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

5.  Differential cis-regulation of human versus mouse TERT gene expression in vivo: identification of a human-specific repressive element.

Authors:  Izumi Horikawa; Y Jeffrey Chiang; Tricia Patterson; Lionel Feigenbaum; Sun-Hee Leem; Eriko Michishita; Vladimir Larionov; Richard J Hodes; J Carl Barrett
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

6.  Understanding the IL-23-IL-17 immune pathway.

Authors:  Brent S McKenzie; Robert A Kastelein; Daniel J Cua
Journal:  Trends Immunol       Date:  2005-11-14       Impact factor: 16.687

7.  Host-reactive CD8+ memory stem cells in graft-versus-host disease.

Authors:  Yi Zhang; Gerard Joe; Elizabeth Hexner; Jiang Zhu; Stephen G Emerson
Journal:  Nat Med       Date:  2005-11-20       Impact factor: 53.440

8.  High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.

Authors:  Friedrich H Schmitz-Winnenthal; Christine Volk; Kaspar Z'graggen; Luis Galindo; Daniel Nummer; Yvonne Ziouta; Marianna Bucur; Jürgen Weitz; Volker Schirrmacher; Markus W Büchler; Philipp Beckhove
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

9.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

Authors:  Aaron P Rapoport; Edward A Stadtmauer; Nicole Aqui; Ashraf Badros; Julio Cotte; Lisa Chrisley; Elizabeth Veloso; Zhaohui Zheng; Sandra Westphal; Rebecca Mair; Nina Chi; Bashi Ratterree; Mary Francis Pochran; Sabrina Natt; Joanne Hinkle; Cheryl Sickles; Ambika Sohal; Kathleen Ruehle; Christian Lynch; Lei Zhang; David L Porter; Selina Luger; Chuanfa Guo; Hong-Bin Fang; William Blackwelder; Kim Hankey; Dean Mann; Robert Edelman; Carl Frasch; Bruce L Levine; Alan Cross; Carl H June
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

10.  Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

Authors:  Joseph A Blansfield; Kimberly E Beck; Khoi Tran; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Suzanne L Topalian; Leah R Haworth; Catherine Levy; Steven A Rosenberg; Richard M Sherry
Journal:  J Immunother       Date:  2005 Nov-Dec       Impact factor: 4.456

View more
  112 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

3.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Authors:  Eric F Zhu; Shuning A Gai; Cary F Opel; Byron H Kwan; Rishi Surana; Martin C Mihm; Monique J Kauke; Kelly D Moynihan; Alessandro Angelini; Robert T Williams; Matthias T Stephan; Jacob S Kim; Michael B Yaffe; Darrell J Irvine; Louis M Weiner; Glenn Dranoff; K Dane Wittrup
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

4.  Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Authors:  Eynav Klechevsky; Michael Gallegos; Galit Denkberg; Karolina Palucka; Jacques Banchereau; Cyril Cohen; Yoram Reiter
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 5.  Adoptive immunotherapy: good habits instilled at youth have long-term benefits.

Authors:  Chrystal M Paulos; Megan M Suhoski; Gabriela Plesa; Tianying Jiang; Samik Basu; Tatiana N Golovina; Shuguang Jiang; Nicole A Aqui; Daniel J Powell; Bruce L Levine; Richard G Carroll; James L Riley; Carl H June
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

7.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

8.  Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.

Authors:  David M Barrett; Nathan Singh; Xiaojun Liu; Shuguang Jiang; Carl H June; Stephan A Grupp; Yangbing Zhao
Journal:  Cytotherapy       Date:  2014-01-16       Impact factor: 5.414

9.  "Cell biology meets physiology: functional organization of vertebrate plasma membranes"--the immunological synapse.

Authors:  Silvia Curado; Sudha Kumari; Michael L Dustin
Journal:  Curr Top Membr       Date:  2013       Impact factor: 3.049

Review 10.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.